News

Move is part of strategic plan to optimize commercialization Newly created group to utilize strong locally-led Generics presence to leverage Teva's globally-based Specialty offering Dr. Rob Koremans appointed President and CEO of Global Specialty Medicines Group JERUSALEM--(BUSINESS WIRE)--Apr. 24, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the creation of a Global Specialty Medicines (GSM) group. Dr. Rob Koremans will serve as President and CEO Global Specialty Medicines. He will continue to serve on Teva’s Executive Committee and report to Dr. Jeremy Levin, Read More »

JERUSALEM--(BUSINESS WIRE)--Apr. 9, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its first quarter 2013 financial results on Thursday, May 2, 2013 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its first quarter 2013 results and overall business environment. A Question & Answer session will follow this discussion. In order to participate, please dial the following numbers (at least 10 minutes befor Read More »

Yoo Suk Hong, previous Lilly Korea CEO, recruited as first CEO of Teva-Handok Teva-Handok is scheduled to officially launch in September JERUSALEM & SEOUL, South Korea--(BUSINESS WIRE)--Apr. 8, 2013-- Teva-Handok today announced the appointment of Yoo Suk Hong as the first Chief Executive Officer of the business venture established between Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Handok Pharmaceuticals (KRX: 002390). This business venture was formed in February, 2013 and fo Read More »

JERUSALEM--(BUSINESS WIRE)--Apr. 8, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced the appointment of Ichiro Kikushige as Chief Executive Officer (CEO) of Teva Seiyaku, Japan, effective on May 15, 2013. Mr. Kikushige most recently was Senior Director of Sales for Eli Lilly Japan K.K. Mr. Kikushige will replace Makoto Shimada, currently President and CEO of Teva Seiyaku, who is retiring after having served the pharmaceutical industry in Japan for nearly 40 years. Mr. Shimada will remain at Teva Seiyaku until June 30, Read More »

JERUSALEM--(BUSINESS WIRE)--Mar. 12, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the 2013 Barclays Global Healthcare Conference. Eyal Desheh, Chief Financial Officer, Teva Pharmaceutical Industries Ltd. will present on Thursday, March 14, 2013.       What: Read More »

JERUSALEM--(BUSINESS WIRE)--Feb. 11, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that Dr. Arie Belldegrun was appointed by the Board of Directors of Teva, at its meeting of February 5, 2013, to fill a vacancy on the Board effective immediately. Dr. Belldegrun's term of office will extend until Teva’s 2013 Annual Meeting of Shareholders. “We are pleased to welcome Dr. Belldegrun to our Board. Arie’s extensive experience in the pharmaceutical industry both as a doctor, a business leader and an academi Read More »

JERUSALEM--(BUSINESS WIRE)--Jan. 7, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the J.P. Morgan Healthcare Conference in San Francisco, CA. Dr. Jeremy Levin, President & CEO, Teva Pharmaceutical Industries Ltd., will present on Tuesday, January 8, 2013.     What: Teva Pre Read More »

- Proceeds to be used for repayment of existing debt - JERUSALEM--(BUSINESS WIRE)--Dec. 13, 2012-- Teva Pharmaceutical Industries Limited (NYSE: TEVA) announced today that it successfully priced a debt offering by its special purpose finance subsidiaries, consisting of two tranches: $700,000,000 of 2.250% fixed rate senior notes maturing in March 2020 issued by Teva Pharmaceutical Finance IV, LLC; and $1,300,000,000 of 2.950% fixed rate senior notes maturing in December 2022 issued by Teva Pharmaceutical Finance Company BV The notes will be sold at a price of $999.55 and $998.02 per Read More »

JERUSALEM--(BUSINESS WIRE)--Dec. 13, 2012-- Teva Pharmaceutical Industries Limited (NYSE: TEVA) announced today that Fitch Ratings have assigned to it an initial long term issuer rating of A-, with a stable outlook. The credit rating agency said that the rating reflects Teva’s strategic position as the world's largest generic drug manufacturer, financial discipline, strong cash flow and liquidity, and capital deployment toward debt reduction. “Our decision to obtain a credit rating from Fitch further supports our Read More »

2013 Non-GAAP Diluted EPS of $4.85 to $5.15 JERUSALEM--(BUSINESS WIRE)--Nov. 30, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) provided its current outlook for non-GAAP financial performance for the full year ending December 31, 2013. Financial Targets: Total net revenues of between $19.5-$20.5 billion, consisting of:   Region   Net Revenues United States   $10.0 to $10.6B Europe   $5.5 to $6.1B Rest of World   $3.7 to $4.3B Total net revenues include the following major business lines: Generic medicines (including API) net reve Read More »